EOLS - Evolus, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.79
-0.15 (-1.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.94
Open13.85
Bid13.41 x 800
Ask14.08 x 800
Day's Range13.18 - 14.09
52 Week Range10.22 - 34.49
Volume694,116
Avg. Volume886,998
Market Cap376.922M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Evolus Provides Update on Nuceiva™ Marketing Authorization Application in Europe

    Evolus, Inc. (EOLS) today provided an update on the marketing authorization application (MAA) for Nuceiva™ in Europe that may result in the European Commission (EC) extending its final decision on approval beyond the 90 days previously stated by the company. Evolus was informed by the EMA that the EC has requested supplementary information from the EMA/CHMP as part of their review of the Nuceiva™ MAA.  The EC has the ability to delay its standard timeline if additional information is requested of the EMA/CHMP during its decision-making process.

  • GlobeNewswire11 days ago

    Evolus Accelerates Next Phase of U.S. Launch of Jeuveau™ with ‘#NEWTOX NOW’ Consumer Conversion Program

    Evolus, Inc. (EOLS) today announced the launch of the ‘#NEWTOX NOW’ consumer conversion program following the rapid adoption of the company’s Jeuveau™ Experience Treatment (J.E.T.) program.  Jeuveau™ (prabotulinumtoxinA-xvfs) was introduced to the U.S. market on May 15 and is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyes) in adults.

  • GlobeNewswire19 days ago

    Evolus to Participate in Three Upcoming Investor Conferences

    NEWPORT BEACH, Calif., May 28, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt
    PR Newswire26 days ago

    ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt

    NEWPORT BEACH, Calif., May 21, 2019 /PRNewswire/ -- ALPHAEON Corporation ("ALPHAEON"), announced today that it has completed the sale of 4.0 million shares of common stock in Evolus, Inc. (EOLS) ("Evolus"). ALPHAEON intends to use the net proceeds from this offering to pay off a majority of its $88 million in third-party debt obligations, which are due in June 2019. In lieu of cash, certain of the note holders have elected to convert part of the outstanding portions of their notes into approximately 1.3 million Evolus shares.

  • ALPHAEON Corporation sells 4 million shares in Evolus Inc.
    PR Newswirelast month

    ALPHAEON Corporation sells 4 million shares in Evolus Inc.

    NEWPORT BEACH, Calif., May 15, 2019 /PRNewswire/ -- ALPHAEON Corporation announced today that it has agreed to sell approximately 4.0 million shares of common stock in Evolus, Inc. (EOLS) in an underwritten public offering with Morgan Stanley acting as sole underwriter for the offering. No shares will be sold by Evolus in the offering nor will any of the sale proceeds go to Evolus. ALPHAEON has also granted Morgan Stanley a 30-day option to purchase up to 600,000 additional shares of Evolus common stock. The primary use of proceeds will be to pay down ALPHAEON's outstanding secured debt obligations. The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was previously filed by Evolus with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there by any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

  • GlobeNewswirelast month

    Evolus Announces First Shipment of Jeuveau™ (prabotulinumtoxinA-xvfs) to Customers in the United States

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that with the U.S. launch of Jeuveau™ (prabotulinumtoxinA-xvfs), there’s a #NEWTOX on the market. Jeuveau™ was approved by U.S. Food and Drug Administration (FDA) in February 2019 for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyes) in adults and is the first neurotoxin in the U.S. developed with a specific focus in aesthetics. Evolus is planning to launch the Jeuveau™ Experience Treatment (J.E.T.) through approximately 3,000 accounts nationwide.

  • How Many Evolus, Inc. (NASDAQ:EOLS) Shares Do Institutions Own?
    Simply Wall St.2 months ago

    How Many Evolus, Inc. (NASDAQ:EOLS) Shares Do Institutions Own?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Evolus, Inc. (NASDAQ:EOLS) should be aware of the most powerful shareholder groups...

  • Evolus, Inc. (EOLS) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Evolus, Inc. (EOLS) Q1 2019 Earnings Call Transcript

    EOLS earnings call for the period ending March 31, 2019.

  • GlobeNewswire2 months ago

    Evolus Reports First Quarter 2019 Financial Results

    NEWPORT BEACH, Calif., April 30, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire2 months ago

    Evolus to Participate in Two Upcoming Investor Conferences

    IRVINE, Calif., April 29, 2019 -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?
    Zacks2 months ago

    Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?

    Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.

  • Benzinga2 months ago

    3 Stocks To Watch Ahead Of Earnings

    These three health and technology stocks are seeing technical strength ahead of upcoming earnings. Evolus, Inc. (NASDAQ: EOLS ) gained 50 cents to $26.44 on 537,100 shares Wednesday.  The performance beauty ...

  • GlobeNewswire2 months ago

    Evolus Receives Positive CHMP Opinion for Nuceiva™ in the European Union

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the Nuceiva™ marketing authorization application. The CHMP opinion is a scientific recommendation for marketing authorization to the European Commission, which will now review the recommendation and deliver its final decision on the Company’s marketing authorization application.

  • Harry Boxer’s three stocks to watch this week
    MarketWatch2 months ago

    Harry Boxer’s three stocks to watch this week

    Evolus Inc. (EOLS) gained 50 cents to $26.44 on 537,100 shares traded Wednesday. The performance-beauty company said it will release earnings after the close of the stock market April 30. Extreme Networks Inc. (EXTR) rose 29 cents to $8.26 on 2.1 million shares traded Wednesday, nearly 1 1/2 times its average volume.

  • Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?
    Zacks2 months ago

    Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?

    With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.

  • Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?
    Zacks2 months ago

    Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?

    Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.

  • Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?
    Zacks2 months ago

    Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?

    ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.

  • GlobeNewswire2 months ago

    Evolus to Release First Quarter 2019 Financial Results and Provide a Business Update on Tuesday, April 30, 2019

    IRVINE, Calif., April 24, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?
    Zacks2 months ago

    Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?

    Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.

  • Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?
    Zacks2 months ago

    Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?

    Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.

  • GlobeNewswire2 months ago

    Evolus Announces Publication of Largest Aesthetic Head-to-Head Pivotal Trial Comparing Jeuveau™ and BOTOX® in Aesthetic Surgery Journal

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the publication of the European and Canadian Phase III head-to-head pivotal trial results in the April issue of Aesthetic Surgery Journal. “We are pleased that these data were accepted and published in the Aesthetic Surgery Journal, which is added validation of the rigor of the study,” said Rui Avelar, MD, Chief Medical Officer and Head of Research & Development. “The results of this study are compelling and reinforce the clinical performance of Jeuveau™, which is the first 900 kDa product to enter the U.S. market in nearly 30 years,” said David Moatazedi, President and Chief Executive Officer.

  • 3 Small-Cap Biotech Stocks to Watch Now
    Motley Fool2 months ago

    3 Small-Cap Biotech Stocks to Watch Now

    These under-the-radar stocks could be poised to make big moves in the coming months.

  • GlobeNewswire2 months ago

    Evolus Provides Regulatory Update on Nuceiva™ in the European Union

    Nuceiva™ (branded Jeuveau™ in the United States) is being evaluated by the EMA for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age. “We are actively addressing the CHMP’s final few questions in accordance with their timelines, which will enable them to adopt their formal opinion on our MAA during the April Committee meeting,” said Rui Avelar, MD, Chief Medical Officer and Head of Research & Development at Evolus, Inc.  “In the second quarter, in addition to an opinion in Europe, we look forward to publishing the largest head-to-head aesthetic pivotal trial of our neurotoxin versus BOTOX®, which was conducted in Europe and Canada.